Xbrane Talks Launch Plans After Initiating US Xlucane Study

 
• By Grace Montgomery

Having initiated the US clinical trial for its Xlucane (ranibizumab) biosimilar, Xbrane describes the competitive situation for the ophthalmology drug in the US and Europe as “promising”, detailing plans to launch in the second quarter of 2022. The Swedish biosimilars specialist also offers updates on the rest of its pipeline.

Start
Xbrane has begun the clinical trial for its ranibizumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products